Structured evidence table for Berberine Blood Lipids Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Blood Lipids Randomized Trial | As such, it may be beneficial to use berberine combined with statins in people with hyperlipidemia, especially for those with statin intolerance or partial intolerance, and those with diabetes or at high risk of diabetes. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Blood Lipids Randomized Trial | Berberine has been recommended by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients, however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Blood Lipids Randomized Trial | Despite of the benefits on lipid profile and glucose metabolism, the effect of berberine on the risk of IHD and diabetes has not been clarified. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Blood Lipids Randomized Trial | 1 2 3 4 Ischemic heart disease (IHD) is the single leading cause of mortality and poses a heavy burden on healthcare, which accounts for ~16% of all deaths globally. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Blood Lipids Randomized Trial | Evidence demonstrated that high-fat diets, in particular saturated fats, elevate plasma ceramide levels, which are strongly associated with insulin resistance and T2DM. | 3 | Collins K (2026) | Ceramides and Type 2 Diabetes: A Scoping Review of Mechanisms, Insulin Resistance, and Nutritional Interventions. |
| Berberine Blood Lipids Randomized Trial | Collectively, the evidence supports a mechanistic and associative link between ceramides and T2DM. | 3 | Collins K (2026) | Ceramides and Type 2 Diabetes: A Scoping Review of Mechanisms, Insulin Resistance, and Nutritional Interventions. |
| Berberine Blood Lipids Randomized Trial | It highlights the emerging potential of plasma ceramides as biomarkers for insulin resistance and disease risk. | 3 | Collins K (2026) | Ceramides and Type 2 Diabetes: A Scoping Review of Mechanisms, Insulin Resistance, and Nutritional Interventions. |
| Berberine Blood Lipids Randomized Trial | This scoping literature review examined the relationship between ceramides and type 2 diabetes mellitus (T2DM), as well as nutrition interventions that are shown to lower circulating ceramides. | 3 | Collins K (2026) | Ceramides and Type 2 Diabetes: A Scoping Review of Mechanisms, Insulin Resistance, and Nutritional Interventions. |
Source documents